Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026
Vaxart Provides Business Update; Expects Net Proceeds From $40M Offering And Reimbursment Under Project NextGen Award Of Up To $453M To Extend Cash Runaway Into 2026
Vaxart提供業務更新；預計在40M的融資和NextGen項目獎勵下獲得的淨收益高達453M美元，將現金儲備延長至2026年。
— Cash runway extended into 2026 —
現金儲備持續到2026年——
— Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million —
獲得迄今爲止最大的BARDA NextGen項目獎勵之一，高達4.53億美元——
— Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs —
公司資本充足，有能力實現COVID-19和諾如病毒計劃的多個關鍵臨床和監管里程碑——
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。